GB9926983D0 - Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases - Google Patents

Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases

Info

Publication number
GB9926983D0
GB9926983D0 GBGB9926983.9A GB9926983A GB9926983D0 GB 9926983 D0 GB9926983 D0 GB 9926983D0 GB 9926983 A GB9926983 A GB 9926983A GB 9926983 D0 GB9926983 D0 GB 9926983D0
Authority
GB
United Kingdom
Prior art keywords
quinolin
methoxy
diseases
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9926983.9A
Other versions
GB2356138A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to GB9926983A priority Critical patent/GB2356138A/en
Publication of GB9926983D0 publication Critical patent/GB9926983D0/en
Priority to AU15189/01A priority patent/AU1518901A/en
Priority to PCT/EP2000/010922 priority patent/WO2001035960A1/en
Publication of GB2356138A publication Critical patent/GB2356138A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9926983A 1999-11-15 1999-11-15 Use of substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases Withdrawn GB2356138A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9926983A GB2356138A (en) 1999-11-15 1999-11-15 Use of substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases
AU15189/01A AU1518901A (en) 1999-11-15 2000-11-06 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases
PCT/EP2000/010922 WO2001035960A1 (en) 1999-11-15 2000-11-06 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9926983A GB2356138A (en) 1999-11-15 1999-11-15 Use of substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases

Publications (2)

Publication Number Publication Date
GB9926983D0 true GB9926983D0 (en) 2000-01-12
GB2356138A GB2356138A (en) 2001-05-16

Family

ID=10864540

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9926983A Withdrawn GB2356138A (en) 1999-11-15 1999-11-15 Use of substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases

Country Status (3)

Country Link
AU (1) AU1518901A (en)
GB (1) GB2356138A (en)
WO (1) WO2001035960A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3900261A1 (en) * 1988-05-31 1989-12-07 Bayer Ag SUBSTITUTED 4- (CHINOLIN-2-YL-METHOXY) PHENYL-ACETIC ACID DERIVATIVES
DE4112533A1 (en) * 1991-04-17 1992-10-22 Bayer Ag METHOD FOR THE PRODUCTION OF ENANTIOMER-PURE SUBSTITUTED (CHINOLIN-2-YL-METHOXY) PHENYL ACETIC ACIDS

Also Published As

Publication number Publication date
GB2356138A (en) 2001-05-16
WO2001035960A1 (en) 2001-05-25
AU1518901A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
HK1087616A1 (en) Use of (-)(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricaemia
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
NO20020764D0 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
HUP0204182A3 (en) Use of fumaric acid derivatives for treating mitochondrial diseases
HK1048443A1 (en) Fatty acid derivative for the treatment of external secretion disorders
NO20001962D0 (en) Therapeutic use of quinoline derivatives
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
SI1487828T1 (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
EE200200305A (en) Novel azabicyclooctane derivatives used in the treatment of cardiac arrhythmias
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HUP0103788A3 (en) Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
NO20020784D0 (en) Medication for the treatment of fractures
NO20012541D0 (en) Use of phosphonomauric acid derivatives for the treatment of infections
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
NO20012612L (en) Isonipecotamides for the treatment of integrin-mediated diseases
GB9926983D0 (en) Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases
NO20013407D0 (en) Process for the preparation of quinoline carbaldehyde
GB0028484D0 (en) Imidazolone derivatives for the treatment of viral diseases
AU1022501A (en) Use of compositions for the caring treatment of the skin
NO20012540D0 (en) Use of phosphonomauric acid derivatives for the treatment of infections
AU4101900A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
AU2001282410A1 (en) N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)